New Risk • Jul 17
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Canadian stocks, typically moving 13% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (13% average weekly change). Market cap is less than US$100m (CA$38.4m market cap, or US$27.4m). Announcement • Jul 14
MediPharm Labs Corp. Announces Positive Phase II LiBBY Trial Results Demonstrating Significant Reduction in Agitation Associated with Advanced Alzheimer's Disease and Dementia MediPharm Labs Corp. announced positive results from the Phase II LiBBY (Life’s End Benefits of Cannabidiol and Tetrahydrocannabinol) clinical trial evaluating the Company’s proprietary oral cannabinoid formulation for the treatment of agitation in patients with advanced dementia. The LiBBY randomized, double-blind, placebo-controlled study met its primary endpoint and demonstrated statistically significant improvements in agitation symptoms compared with placebo, with benefits observed as early as two weeks and sustained throughout the 12-week treatment period. Supportive findings from the open-label extension phase further demonstrated durability of response over time. The study evaluated MediPharm Labs’ proprietary oral cannabinoid formulation, which was developed and supplied exclusively by MediPharm Labs for use in the trial. Key findings presented at AAIC included: The primary endpoint was achieved, demonstrating statistically significant improvement in agitation symptoms at week 2 as measured by the Cohen-Mansfield Agitation Inventory (“CMAI”). Treatment benefits were sustained throughout the 12-week double-blind treatment period. Statistically significant improvements were observed in overall clinical status compared with placebo. Open-label extension findings supported durability of response and continued patient benefit over time. The Company is reviewing the full study results and evaluating potential next steps, including possible regulatory activities, additional clinical development opportunities and potential strategic collaborations. The LiBBY study highlights MediPharm’s ability to support complex international clinical research programs involving cannabinoids. The Company developed and manufactured the proprietary formulation used in the study and supplied clinical trial materials into the United States through a highly regulated cross-border supply chain. The Company retains ownership of the proprietary formulation and related MediPharm intellectual property and has rights to access and use study data generated in the trial to support future regulatory submissions, patent filings, future research activities and other development initiatives related to MediPharm’s business and products. In connection with the study and related development activities, MediPharm continues to pursue intellectual property protection, including, but not limited to, filing one or more patent applications, for protection of the proprietary formulation, given the positive results from the clinical trial for the treatment of agitation associated with Alzheimer’s disease and other dementias. MediPharm maintains a US FDA-registered facility, a Drug Establishment Licence and multiple international GMP certifications, enabling the company to participate in pharmaceutical development programs. The Company has supported more than 10 clinical studies across multiple indications and welcomes opportunities to collaborate with academic institutions, research organizations and pharmaceutical companies advancing cannabinoid-based therapeutics. The LiBBY study is led by investigators at the Keck School of Medicine of the University of Southern California and funded by the National Institute on Aging, part of the U.S. National Institutes of Health, with additional funding provided by the Alzheimer’s Association through project SG-25-1440079. The study was conducted through the Alzheimer’s Clinical Trials Consortium and coordinated by the USC Epstein Family Alzheimer’s Therapeutic Research Institute in collaboration with leading academic research institutions across the United States. The Phase II study evaluated an oral combination of THC and CBD for the treatment of agitation in hospice-eligible patients with Alzheimer’s disease or other dementias. The randomized, multicentre, double-blind, placebo-controlled phase included a 12-week treatment period, followed by an optional open-label extension phase for eligible participants. Announcement • Jun 18
MediPharm Labs Corp. Approves Board Changes MediPharm Labs Corp. at its annual and special meeting held on June 17, 2026 approved the following his re-election as a director, Keith Strachan was appointed Chair of the Board. Chris Taves, outgoing Chair, and Chris Halyk did not stand for re-election. 
